Non-cysteine linked MUC1 cytoplasmic dimers are required for Src recruitment and ICAM-1 binding induced cell invasion

[1]  F. Musumeci,et al.  Novel dual Src/Abl inhibitors for hematologic and solid malignancies , 2010, Expert opinion on investigational drugs.

[2]  Michael L. Gatza,et al.  A pathway-based classification of human breast cancer , 2010, Proceedings of the National Academy of Sciences.

[3]  M. Thelen,et al.  Chemokine receptor oligomerization: functional considerations. , 2010, Current opinion in pharmacology.

[4]  J. Balko,et al.  MUC1 is a downstream target of STAT3 and regulates lung cancer cell survival and invasion. , 2009, International journal of oncology.

[5]  L. Yin,et al.  Direct targeting of the mucin 1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells. , 2009, Cancer research.

[6]  Paul Dent,et al.  Synergistic combinations of signaling pathway inhibitors: mechanisms for improved cancer therapy. , 2009, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[7]  Donald W Kufe,et al.  MUC1-induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment , 2009, Proceedings of the National Academy of Sciences.

[8]  C. Perou,et al.  Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  R. Nicholson,et al.  Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells , 2009, Breast Cancer Research and Treatment.

[10]  D. Carson.  The Cytoplasmic Tail of MUC1: A Very Busy Place , 2008, Science Signaling.

[11]  R. Jove,et al.  SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells , 2008, Molecular Cancer Therapeutics.

[12]  Jaehong Park,et al.  A Minimal Fragment of MUC1 Mediates Growth of Cancer Cells , 2008, PloS one.

[13]  Nirosha Gunasekera,et al.  MUC1 Initiates Src-CrkL-Rac1/Cdc42–Mediated Actin Cytoskeletal Protrusive Motility after Ligating Intercellular Adhesion Molecule-1 , 2008, Molecular Cancer Research.

[14]  Zhenglong Yuan,et al.  Down-regulation of MUC1 in cancer cells inhibits cell migration by promoting E-cadherin/catenin complex formation. , 2007, Biochemical and biophysical research communications.

[15]  D. Kufe,et al.  Nuclear Import of the MUC1-C Oncoprotein Is Mediated by Nucleoporin Nup62* , 2007, Journal of Biological Chemistry.

[16]  Jing Jiang,et al.  Role of the growth hormone (GH) receptor transmembrane domain in receptor predimerization and GH-induced activation. , 2007, Molecular endocrinology.

[17]  S. Rabbani,et al.  A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo. , 2007, Cancer research.

[18]  R. Nicholson,et al.  Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancer. , 2006, Endocrine-related cancer.

[19]  I. Barnea,et al.  MUC1 gene overexpressed in breast cancer: structure and transcriptional activity of the MUC1 promoter and role of estrogen receptor alpha (ERα) in regulation of the MUC1 gene expression , 2006, Molecular Cancer.

[20]  J. M. García-Martínez,et al.  Role of c-Src in Human MCF7 Breast Cancer Cell Tumorigenesis* , 2006, Journal of Biological Chemistry.

[21]  S. Gendler,et al.  MUC1 cytoplasmic tail detection using CT33 polyclonal and CT2 monoclonal antibodies in breast and colorectal tissue. , 2006, Histology and histopathology.

[22]  Denny G. A. Johansson,et al.  Autoproteolysis coupled to protein folding in the SEA domain of the membrane-bound MUC1 mucin , 2006, Nature Structural &Molecular Biology.

[23]  R. Nicholson,et al.  Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells , 2006, Breast Cancer Research and Treatment.

[24]  G. Song,et al.  Regulated dimerization of the thyrotropin-releasing hormone receptor affects receptor trafficking but not signaling. , 2005, Molecular endocrinology.

[25]  N. Smorodinsky,et al.  The MUC1 SEA Module Is a Self-cleaving Domain* , 2005, Journal of Biological Chemistry.

[26]  S. Gendler,et al.  Muc1 affects c-Src signaling in PyV MT-induced mammary tumorigenesis , 2005, Oncogene.

[27]  J. Chow,et al.  MUC1 Mediates Transendothelial Migration in vitro by Ligating Endothelial Cell ICAM-1 , 2005, Clinical & Experimental Metastasis.

[28]  L. Yin,et al.  MUC1 Oncoprotein Activates the FOXO3a Transcription Factor in a Survival Response to Oxidative Stress* , 2004, Journal of Biological Chemistry.

[29]  Lars I Leichert,et al.  Protein Thiol Modifications Visualized In Vivo , 2004, PLoS biology.

[30]  J. Hugh,et al.  MUC1 Initiates a Calcium Signal after Ligation by Intercellular Adhesion Molecule-1* , 2004, Journal of Biological Chemistry.

[31]  J. Hanson,et al.  MUC1 expression in primary breast cancer: the effect of tamoxifen treatment , 2001, Breast Cancer Research and Treatment.

[32]  A. V. D. Stolpe,et al.  Intercellular adhesion molecule-1 , 2020, Journal of Molecular Medicine.

[33]  L. Yin,et al.  Human MUC1 Carcinoma Antigen Regulates Intracellular Oxidant Levels and the Apoptotic Response to Oxidative Stress* , 2003, Journal of Biological Chemistry.

[34]  Ursula Jakob,et al.  Not every disulfide lasts forever: disulfide bond formation as a redox switch. , 2003, Antioxidants & redox signaling.

[35]  S. Wołczyński,et al.  Biosynthesis of MUC1 mucin in human endometrial adenocarcinoma is modulated by estradiol and tamoxifen , 2003, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[36]  C. A. Blau,et al.  Control of Myoblast Proliferation with a Synthetic Ligand* , 2001, The Journal of Biological Chemistry.

[37]  D. Edwards,et al.  Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases. , 2001, Molecular cell.

[38]  R. Black,et al.  Growth Hormone (GH)-induced Dimerization Inhibits Phorbol Ester-stimulated GH Receptor Proteolysis* , 2001, The Journal of Biological Chemistry.

[39]  M. Pasdar,et al.  The importance of MUC1 cellular localization in patients with breast carcinoma , 2001, Cancer.

[40]  D. Meerzaman,et al.  Construction and characterization of a chimeric receptor containing the cytoplasmic domain of MUC1 mucin. , 2000, American journal of physiology. Lung cellular and molecular physiology.

[41]  Y Zhang,et al.  Disulfide Linkage of Growth Hormone (GH) Receptors (GHR) Reflects GH-induced GHR Dimerization , 1999, The Journal of Biological Chemistry.

[42]  H. Fujiwara,et al.  A critical role for a peritumoral stromal reaction in the induction of T-cell migration responsible for interleukin-12-induced tumor regression. , 1999, Cancer research.

[43]  Jing Jiang,et al.  Growth hormone induces detergent insolubility of GH receptors in IM-9 cells. , 1997, American journal of physiology. Endocrinology and metabolism.

[44]  L. Pilarski,et al.  The breast mucin MUCI as a novel adhesion ligand for endothelial intercellular adhesion molecule 1 in breast cancer. , 1996, Cancer research.

[45]  I. Brockhausen,et al.  Mechanisms underlying aberrant glycosylation of MUC1 mucin in breast cancer cells. , 1995, European journal of biochemistry.

[46]  A. Alcover,et al.  Evidence for an extended structure of the T-cell co-receptor CD8 alpha as deduced from the hydrodynamic properties of soluble forms of the extracellular region. , 1993, The Journal of biological chemistry.

[47]  J. Parnes.  Molecular biology and function of CD4 and CD8. , 1989, Advances in immunology.

[48]  P. Yaciuk,et al.  Overexpression of the c-src protein does not induce transformation of NIH 3T3 cells. , 1984, Proceedings of the National Academy of Sciences of the United States of America.